CDP Capital Technology Ventures
VC Fund
Montréal, Canada
CDP Capital Technology Ventures is a VC fund in Montréal focused on Medical and Biopharma. CDP Capital-Technology Ventures is out of business. CDP Capital-Technology Ventures is a principle investment firm specializing in building new technology-based companies. The firm seeks to invest in pre-startup and startup, research and development, mergers & acquisitions, expansion into new markets, and management buyouts. The firm alsoraises fund of funds that invest in North American and European venture capital funds. The firm seeks to invest in companies engaged in life sciences such as including biotechnology, pharmaceuticals, medical instrumentation; information technology; energy technologies; industrial technologies such as aeronautical and environmental. It also seeks to invest in communication and storage. CDP Capital-Technology Ventures was launched in 1995 and is an operating subsidiary of CDP Capital – Private Equity.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 9%
Last updated:
For AI agents: llms.txt
Industries CDP Capital Technology Ventures invests in
Stages CDP Capital Technology Ventures invests in
Countries CDP Capital Technology Ventures invests in
Investment Focus
Industry
- Medical 2 (18%)
- Biopharma 2 (18%)
- Health Care 2 (18%)
- Biotechnology 2 (18%)
- Manufacturing 2 (18%)
Stage
- Series B 5 (45%)
- Funding Round 2 (18%)
- Series A 1 (9%)
- Series C 1 (9%)
- Series D 1 (9%)
Country
- United States 7 (64%)
- Canada 2 (18%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
TargeGen
|
TargeGen, Inc., a vascular biology-focused biopharmaceutical company, discovers and develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis), and inflammation. The company offers its products for the treatment of human diseases, such as heart attack, cancer, and eye diseases; vascularleakage, edema, and the unwanted growth of new blood vessels; pleural effusions, arthritis, pulmonary edema, transplant ischemia, ARDS, brain inflammation, hypovolemia (acute blood loss) CNS disorders, and other serious medical conditions. It serves macular degeneration, diabetic macular edema, and diabetic retinopathy markets. The company was founded in 2002 and is based in San Diego, California. It was acquired by | $40M / Series D / Jul 12, 2007 | |
Xanthus Pharmaceuticals
|
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders. | $25M / Series B / Dec 01, 2006 | |
Entrisphere
|
Entrisphere, Inc. supplies access network equipment for the broadband service providers. Its products include BLM 1500, a multi-service access platform that provides POTS, HiCap, IPTV, DSL, B-PON and GPON, voice over packet, and Ethernet interfaces from a single chassis; and T-series of ONTs and ONUs, which support deployments, including singlefamily units, small business units, multiple dwelling units, multiple tenant units, and in fiber to the curb and fiber to the business. The company also provides Entriview EMS that provides centralized control of BLM 1500 network with FCAPS functionality; and OSP cabinets, which enable voice, data, and video services to be deployed over copper or fiber from remote locations. In addition, it offers support services, such as network planning, consultation, installation, configuration, training, project management, maintenance, and software support. The company was founded in 2000 and is based in Santa Clara, California. As of February 12, 2007, Entrisphere, Inc. operates as subsidiary of LM Ericsson Telephone Co. | $75M / Series C / May 09, 2005 | |
SiGe Semiconductor
|
SiGe Semiconductor, Inc., a fabless semiconductor company, designs and offers radio frequency (RF) integrated circuits and multi-chip modules for wireless consumer electronics market. It offers wireless LAN front end modules, dual band front end modules, and discrete power amplifiers; WiMAX power amplifiers/front end modules and transceivers;GPS radio ICs and GPS receivers; and Bluetooth power amplifiers. The company, through a network of distributors, offers its RF solutions to computing, home entertainment, and mobile device applications in the consumer electronics markets in Asia, Europe, the Middle-East, and North America. | $8.5M / Jan 01, 2005 | |
Stirling Power
|
Stirling Power is a design, engineering, and manufacturing company, continually developing new solutions for the efficient generation of clean, distributed power.Stirling Power is widely respected as one of the world’s leading Stirling engine companies, offering more than 35 years of history, experience, and expertise in Stirling enginetechnology and distributed power generation. | $29.6M / Series B / Apr 28, 2004 | |
TransMedics
|
TransMedics provides technology and clinical service solutions, service for heart and lung transplant volume, clinical outcomes, and reduce learning curves. | $27.6M / Series B / Jan 27, 2004 | |
|
TargeGen
|
TargeGen, Inc., a vascular biology-focused biopharmaceutical company, discovers and develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis), and inflammation. The company offers its products for the treatment of human diseases, such as heart attack, cancer, and eye diseases; vascularleakage, edema, and the unwanted growth of new blood vessels; pleural effusions, arthritis, pulmonary edema, transplant ischemia, ARDS, brain inflammation, hypovolemia (acute blood loss) CNS disorders, and other serious medical conditions. It serves macular degeneration, diabetic macular edema, and diabetic retinopathy markets. The company was founded in 2002 and is based in San Diego, California. It was acquired by | $30M / Series B / Jan 15, 2004 | |
|
Xanthus Pharmaceuticals
|
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders. | $30.8M / Series B / Dec 12, 2003 | |
|
Intelligent Photonics Control
|
Photonics Control delivers sophisticated, intelligent and cost-effective solutions across a whole range of optical devices. | $10.1M / Series B / Jun 30, 2003 | |
|
Ammasso
|
Ammasso, Inc., a server-to-server networking company, develops and delivers RDMA-enabled Ethernet-based products. It provides advanced network protocol acceleration for information technology professionals. The company’s interconnect products extend and integrate with Ethernet solutions for connectivity and manageability. Its products are used intechnical and grid computing; clustered databases; storage infrastructures, including IP storage; and enterprise applications. The company delivers its products through a network of partners. Ammasso, Inc. was founded in 2002 and is based in Boston, Massachusetts. | $10M / Series A / Jun 23, 2003 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does CDP Capital Technology Ventures invest in?
CDP Capital Technology Ventures invests primarily in Medical, Biopharma and Health Care startups, most often at Series B and Funding Round stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did CDP Capital Technology Ventures last invest?
The most recent investment recorded for CDP Capital Technology Ventures closed in Jul 2007. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
